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Abstract
The neuropeptide somatostatin has been suggested to play an important role during neuronal development in addition to
its established modulatory impact on neuroendocrine, motor and cognitive functions in adults. Although six somatostatin G
protein-coupled receptors have been discovered, little is known about their distribution and function in the developing
mammalian brain. In this study, we have first characterized the developmental expression of the somatostatin receptor
sst2A, the subtype found most prominently in the adult rat and human nervous system. In the rat, the sst2A receptor
expression appears as early as E12 and is restricted to post-mitotic neuronal populations leaving the ventricular zone. From
E12 on, migrating neuronal populations immunopositive for the receptor were observed in numerous developing regions
including the cerebral cortex, hippocampus and ganglionic eminences. Intense but transient immunoreactive signals were
detected in the deep part of the external granular layer of the cerebellum, the rostral migratory stream and in tyrosine
hydroxylase- and serotonin- positive neurons and axons. Activation of the sst2A receptor in vitro in rat cerebellar
microexplants and primary hippocampal neurons revealed stimulatory effects on neuronal migration and axonal growth,
respectively. In the human cortex, receptor immunoreactivity was located in the preplate at early development stages (8
gestational weeks) and was enriched to the outer part of the germinal zone at later stages. In the cerebellum, the deep part
of the external granular layer was strongly immunoreactive at 19 gestational weeks, similar to the finding in rodents. In
addition, migrating granule cells in the internal granular layer were also receptor-positive. Together, theses results strongly
suggest that the somatostatin sst2A receptor participates in the development and maturation of specific neuronal
populations during rat and human brain ontogenesis.
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Introduction
Only a restricted number of neuropeptides have been reported
to play a role in the fetal and early post-natal brain, among the
region-specific factors that control cell proliferation, migration and
differentiation during brain development. This is in sharp contrast
with the extensive literature reporting various and robust
physiological functions of neuropeptides in the adult central
nervous system. The relative lack of specific antibodies against
neuropeptide receptors might account for such discrepancy.
Precise information on the regional and cellular localization of
receptors is indeed required to ascribe a potential neurodevelop-
mental role to a given neuropeptide.
The neuropeptide somatostatin (somatotropin release inhibiting
factor, SRIF) [1] has a wide variety of biological roles [1–3]. In the
adult brain, SRIF regulates neuroendocrine, motor and cognitive
functions [4,5]. Perturbation of somatostatinergic neurotransmis-
sion has been demonstrated in temporal lobe epilepsy [6–8],
ischemia [9,10] and Alzheimer’s disease [11].
The five SRIF receptors (sst1–sst5) belong to the family of G
protein-coupled receptors (GPCRs) and bind the native peptides
SRIF-14, SRIF-28 and the more recently discovered neuropeptide
cortistatin [12] with high affinity [1,13]. While sst1, sst3, sst4 and
sst5 genes each generate a single receptor protein, alternative
splicing of the sst2 mRNA gives rise to two protein isoforms, sst2A
and sst2B [14,15]. In the adult mammalian brain, converging
evidence suggests that the sst2A receptor exerts a predominant
role in the transduction of SRIF actions [1,4,13].
In the developing brain, there is now evidence that like the
pituitary adenylate cyclase-activating peptide (PACAP) [16] and
neuropeptide Y (NPY) [17,18], SRIF may also play an important
role in neuronal development [19]. This could be mediated by the
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5509sst2 receptor type since sst2 receptor mRNA [20–22] and binding
sites [23–28] are predominant in the developing rat and human
brain. In addition, the sst2 receptor gene has recently been
demonstrated to be in the top 40 genes (out of 20 000) up-
regulated during neuronal development [29], suggesting a specific
role for this receptor during this period.
Because the ontogenic distribution of the sst2A receptor at the
protein level has not yet been determined, the aim of the present
study was to localize this receptor during rat brain ante- and post-
natal development (E10-P21). Sst2A receptor distribution was
studied in parallel in the human prenatal cerebral cortex and
cerebellum from gestational week 8 to birth. In an attempt to
elucidate the functional role of the sst2A receptor during early
neuronal development, the effect of sst2A receptor activation on
neuronal migration and neurite patterning was also analyzed in
vitro in cerebellar microexplants and primary hippocampal
neurons, respectively.
Results
Rhombencephalon and cerebellum
Cells expressing the sst2A receptor were first detected at E13 in
the rhombomeres (Fig. 1). Round, small (,7 mm) and densely
packed immunoreactive cells were located along the outer limit of
the ventricular zone, in the marginal zone, throughout rhombo-
meres r1 to r6. Immunoreactive processes were apparent in the
ventricular zone, extending perpendicularly to the ventricle. Only
rare colocalization with the proliferation marker Ki-67 was
observed demonstrating that most of sst2A receptor-positive cells
were not proliferating ones (Fig. 1B–B0, F–F0). Double-labeling
with the b-tubulin marker confirmed that this population of sst2A
receptor-expressing cells was mostly post-mitotic neurons. In
addition to this cell population, the sst2A receptor was also
expressed by round and small post-mitotic neurons extending
caudally to the nascent reticular formation and spinal cord. At
E13, intense sst2A receptor immunoreactivity was visualized in the
roots of several cranial nerves including the facial (7n) (Fig. 1G–
G0), trigeminal and cochlear nerves. This labeling was no longer
observed after E15. From E13 to E16, the number of sst2A
receptor expressing cells became higher in the lateral reticular
formation. These cells also expressed the b-tubulin marker.
Between E15 and E17, most of serotonin (5-HT) positive cells,
forming longitudinal columns on both sides of the floor plate from
the developing dorsal raphe nucleus toward the raphe magnus
nucleus, were immunoreactive for the sst2A receptor (Fig. 2).
Neuronal processes as well as longitudinal and transversal fibers
immunoreactive for 5-HT were positive for sst2A receptor
immunoreactivity (Fig. 2D–D9). Rhombencephalic serotoninergic
neurons also expressed the receptor. From E17 onwards, sst2A
receptor immunoreactivity decreased gradually in the developing
brainstem. Only very weak receptor immunoreactivity was
apparent at E21 throughout brainstem nuclei.
In the developing cerebellum, immunopositive cells for the
receptor located along the outer border of the cerebellar
neuroepithelium were apparent as early as E13. At E14, intense
receptor immunostaining was detected in the proliferative zone of
the upper component of the rhombic lip (Fig. 3). This latter region
corresponds to the germinal zone for the progenitors of the
external granular layer (EGL). The vast majority of these sst2A
positive cells migrating towards the future site of the EGL were
post-mitotic, although some of them still expressed the prolifer-
ative marker Ki-67. From E14 to P10 the internal sublamina of
the EGL strongly expressed sst2A receptor immunoreactivity. At
E16, immunogold particles labeling the receptor were visualized
by electron microscopy at the inner side of plasma membrane of
round or elongated-shaped cells in the EGL (Fig. 3D,E), suggesting
that receptors are efficiently targeted to active sites and could be
functional. The proportion of membrane-associated receptor was
38.2662.83% of the total number of receptors. In vivo agonist-
induced internalization and consequent redistribution of the
receptor in intracytoplasmic domains is a powerful tool to
demonstrate that receptors reach plasma membrane and can be
activated by agonists, as previously demonstrated in the adult rat
brain [30–32]. In keeping with results obtained by electron
microscopy, incubation of E16 brains with the sst2 receptor
agonist octreotide induced redistribution of receptor immunore-
activity in the EGL (Fig. 3F,G). At P5, double-labeling
experiments demonstrated that most of the sst2A receptor-
expressing cells were not Ki-67-positive (Fig. 3I–I0) but colocalized
with the neuronal marker NeuN (Fig. 3J–J0). The sst2A receptor
was not expressed within the Purkinje cell layer. Beginning on
E18, another important group of sst2A receptor-positive cells
appeared to exit rostrally and ventrally from the rhombic lip
toward the brainstem. Another pathway appeared to exit the
rhombic lip dorsally toward the cerebellar cortex and disperse in a
fountain-like spray. Receptor expressing cells were then gradually
found in the developing internal granular layer (IGL). At P5,
nearly all sst2A receptor-positive cells within the IGL also
expressed the calcium-binding protein calretinin (Fig. 3K–K0).
Conversely, nearly all of calretinin-positive cells were also positive
for the somatostatin receptor. These sst2A receptor-expressing
cells are most likely glutamatergic interneurons named unipolar
brush cells because of calretinin expression and their oval-shaped
and large perikaryon size displaying a single thick dendrite and a
single axon. After P10, sst2 receptor immunoreactivity was no
more detected in the cerebellum.
As mentioned previously, a subpopulation of cells strongly
immunoreactive for the sst2A receptor, displaying a large and
round cell body with usually a single immunoreactive process were
visible at E18 between the ventral part of the cerebellum and the
ventral part of the hindbrain (Fig. 4A). Interestingly, these cells
also expressed tyrosine hydroxylase (TH) (Fig. 4B–B0), suggesting
that they could be the anlage of the locus coeruleus and/or sublocus
coeruleus. In keeping with this observation, strong receptor
immunoreactivity displaying a honeycomb cellular pattern was
present in the locus from E18. Most of these cells were also
immunoreactive for TH (Fig. 4C–E). The peak of receptor
expression was observed at E21 in this region and persisted until
adulthood.
The expression of the sst2A receptor was also examined in the
developing human cerebellum. Similar to the finding in rodents,
the deep part of the EGL was strongly immunoreactive at
gestational week (GW) 19 (Fig. 5). At this developing stage, SRIF
immunoreactive fibers were also evident in the EGL and SRIF
neuronal cell bodies were present in the deep part of the molecular
layer (Fig. 5B–B09). At GW 20, sst2A receptor labeling was still
intense in the deep part of the EGL (Fig. 5D). Of interest, a very
large proportion of cells (around 80%) expressing the neuronal
marker NeuN was sst2A receptor-immunoreactive in the IGL and
are likely to correspond to migrating granule cells (Fig. 5C–C09,E –
E09). This receptor expression pattern persisted until birth but, like
in rodents, completely disappeared at adulthood.
Mesencephalon–Diencephalon
The first cells immunoreactive for the sst2A receptor appeared
in the lateral component of the superior colliculus at E13.
Receptor expressing cells were then visualized in the inferior
colliculus at E14. At E16, a dense network of immunoreactive cells
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expressed the b-tubulin marker and often displayed one or two
long processes. In the inferior colliculus a similar pattern of
immunoreactive neurons was observed although their density was
less important than in the superior part of the nucleus. In these two
regions, labeled cells and processes persisted until adulthood.
Beginning at E15, intense sst2A receptor immunoreactivity was
detected in the ventral tegmental area (VTA) and the substantia
nigra (SN) (Fig. 6). A peak of labeling was observed at E16 in these
two regions. Receptor immunoreactivity colocalized with TH
immunoreactivity in both neuronal cells and processes (Fig. 6B–
B0). A bundle of sst2A receptor positive axons running in the
dorsal part of the VTA/SN also expressed TH. The receptor
expression, however, remarkably stopped at E18 in these different
regions (Fig. 6C–C0). Between E14 and E16, fibers running
ventrally from the dorsal part of the rhombencephalon to the
developing medial forebrain bundle were strongly immunopositive
for the receptor. In this latter region, sst2A immunoreactive fibers
were positive for TH (Fig. 6D–D0) or for 5-HT (Fig. 6E–E0), and
nearly all of TH or 5-HT fibers were immunopositive for the
receptor. Clear receptor immunoreactivity was observed along the
length of both types of axons and extended to the growing cones.
At the ultrastructural level in the medial forebrain bundle,
structures resembling growth cones and axons displayed very
high densities of intracytoplasmic but also membrane–associated
immunogold particles (Fig. 6F,G). After E16, the receptor
Figure 1. Regional and cellular localization of the sst2A receptor immunoreactivity in sagittal sections of the rat rhombencephalon
at embryonic day 13 (E13). A) Densely packed sst2A receptor-immunoreactive cells are observed in the marginal zone contiguous to the
ventricular zone of the rhombomeres (r1 to r6, arrowheads) and in the lateral reticular formation (LRtF). B–B0) Sst2A receptor-immunoreactive cells
(red) are localized in the marginal zone (B) whereas proliferating cells identified by the proliferation marker Ki-67 (green) are concentrated in the
ventricular zone (B9). The lack of overlap between the two signals (B0) indicates that sst2A receptor-expressing cells are predominantly post-mitotic.
C) The majority of sst2A receptor-immunoreactive cells have small round perikarya and some exhibit immunolabeled processes that are oriented
perpendicularly to the ventricular surface. D) A few sst2A receptor-immunoreactive cells are bipolar, displaying the morphological features of
migrating neurons. E) In the LRtF, cell bodies are strongly sst2A receptor-immunoreactive. F–F0) An sst2A receptor-immunoreactive cell (red in F, F0)
of the LRtF is found to be Ki-67-positive (green in F9,F 0) (arrowheads). The low percentage of colocalization (F0) indicates that the majority of
receptor-expressing cells are post-mitotic. G–G0) The post-mitotic feature of most sst2A receptor-immunoreactive cells (red in G, G0)o ft h e
rhombencephalon is further indicated by the colocalization (G0) with the post-mitotic neuronal marker b-tubulin (green in G9,G 0) (arrowheads), as
illustrated in the facial nucleus. Scale bars: A, 250 mm; B–B0, G–G0,5 0mm; C, E, 20 mm; F, 10 mm.
doi:10.1371/journal.pone.0005509.g001
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PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5509Figure 2. Expression of the sst2A receptor in serotoninergic neurons of the rat brainstem at E16. A) Triple-labeling with sst2A receptor
(red), 5-HT (green) and DAPI (blue) in the ventral part of the brainstem illustrates that most serotoninergic neurons are sst2A receptor
immunoreactive. B,B9 represent magnification of the boxed area in A. Note the extensive colocalization of sst2A receptor and 5-HT in both cell bodies
and processes. C) The sst2A receptor is also expressed in serotoninergic migrating cells in the more dorsal part of the mesencephalon presumably
corresponding to the dorsal raphe nucleus. D,D9 represents magnification of the boxed area in C and illustrates double-labeling in both the soma and
processes of migrating neurons. Scale bars: A, C, 50 mm; B, D, 20 mm.
doi:10.1371/journal.pone.0005509.g002
Sst2A and Brain Development
PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5509Sst2A and Brain Development
PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5509fluorescent labeling progressively decreased both in term of
intensity and of density of immunoreactive fibers. Only a few
fibers were still positive for the receptor at E18 in the medial
forebrain bundle.
At E14, numerous cells and processes, strongly immunoreactive
for the receptor, appeared in the anterior and lateral hypothalamic
area (Fig. 6H–K). From E16 onward, the labeling became fainter
and more diffusely distributed throughout the neuropil, affecting
most of the developing hypothalamic nuclei except for the most
caudal part of the arcuate nucleus. This receptor-immunoreactive
distribution persisted during post-natal development and in
adulthood.
Telencephalon
Beginning at E16, numerous post-mitotic neurons were detected
in the lateral and caudal ganglionic eminence (Fig. 7). They were
small with several short processes, strongly immunoreactive for the
receptor and distributed in the dorso-lateral part of the developing
caudate-putamen, but sparing the proliferative zone bordering the
ventricle. There was a clear demarcation between the distribution
of this immunoreactive neuronal population and the one found in
the cerebral cortex, i.e. the cortico-striatal junction was devoid of
sst2A-immunoreactive neurons. Unlike other developing brain
areas, the caudal ganglionic eminence displayed a relatively low
proportion (10.2860.48%) of membrane-associated receptors as
detected by electron microscopy (Fig. 7D,E). Redistribution of
receptor immunoreactivity was however observed upon agonist
stimulation in this region (Fig. 7H,I). In frontal sections, a stream
of immunoreactive cells emanating from the ventral part of the
caudate-putamen was observed in the ventral parts of the nucleus
accumbens and the olfactory tubercle as well as in the ventral part
of the lateral septum. In more caudal sections passing through the
caudate-putamen this stream was less impressive, although
moderate densities of immunoreactive cells were found in ventral
regions including the bed nucleus and the hypothalamus. From
E16 to P3, a dense population of immunoreactive neurons was
distributed in the dorso-medial part of the caudate-putamen
(Fig. 7J–N). Here, neuronal cells expressing the receptor were post-
mitotic like in other developing structures and were not located in
the vicinity of the ventricle. Immunoreactive cells and dendrites as
well as axonal fibers were found pervading the globus pallidus, the
nucleus accumbens and the olfactory tubercle. Weakly immuno-
reactive fibers and cells were also visualized in the medial and
lateral septum nuclei as well as in the vertical and horizontal limbs
of the diagonal band. More caudally, cell and processes expressing
the sst2A receptor were found in the amygdaloid nuclei. After P3,
the receptor staining became weaker and more diffuse in these
regions and displayed the same pattern of distribution as observed
at adulthood.
The developing cerebral cortex represented the brain structure
with the highest receptor expression throughout prenatal devel-
opment. Sst2A receptor-immunoreactive cells were first detected
in the preplate at E13–14 (Fig. 8A–A09). At E16, sst2A receptor
immunoreactivity was restricted to the subplate/intermediate zone
in which post-mitotic neurons are migrating (Fig. 8B–B09). At E18,
the immunolabeling was very intense in the intermediate zone
(Fig. 8C–C09), in densely packed neurons as well as short processes.
At E21, intense receptor immunoreactivity became apparent in
the subventricular zone and the adjacent deep intermediate zone
(Fig. 8D–D09). With increasing fetal ages, more fibers and
processes tended to become immunoreactive. Although lightly
stained, dispersed bipolar cells with processes oriented perpendic-
ularly to the cortical surface were also apparent above and below
the intermediate zone. Only few immunoreactive cells were seen
in the upper part of the cortical plate and receptor expression was
not visualized in the marginal zone. After birth, the receptor
immunoreactivity pattern and expression changed remarkably.
The labeling was no more observed in the subventricular zone but
became diffuse, homogeneously distributed over the neuropil and
formed a gradient across the cortical layers, from intense in the
superficial layers to very low in the deepest layers (Fig. 8E–E09).
With cortical maturation, this diffuse labeling progressively shifted
to the layers V–VI. Around P14 and thereafter, distribution of
receptor immunoreactivity was similar to that reported in
adulthood, i.e. enriched in the upper part of the layer V and the
deeper part of the layer VI with somatodendritic immunoreactive
profiles and ascending dendrites only occasionally apparent,
scattered in the diffuse sst2A receptor immunostaining. At E16,
the presence of receptor at the plasma membrane was confirmed
by immunogold electron microscopy and represents 30.6463.09%
of the total number of receptors (Fig. 9A–C). Agonist treatment at
this age triggered internalization of receptor immunoreactivity
thereby demonstrating clearly that surface receptors expressed by
these neurons can be activated (Fig. 9D,E).
Because sst2A receptor immunoreactivity was striking in the
developing cortical wall in rats, we next investigated whether the
sst2A receptor is also expressed in the developing human cerebral
cortex (Fig. 10). Receptor immunoreactivity was first detected at
GW 8 in the cortical wall. Because maturation of the human
cerebral cortex follows a latero-medial gradient with an offset of
approximately 15 days, the distribution of receptor immunoreac-
tivity was different between the lateral and the medial parts of the
cerebral cortex. In the latter, the bulk of receptor expression was
visualized in the preplate and in the subventricular zone
Figure 3. Regional, cellular and subcellular distribution of sst2A receptor immunoreactivity in sagittal sections of the rat
cerebellum during pre- and postnatal development. A) At E14, sst2A receptor immunoreactivity is detected in the developing cerebellum
(boxed area). Note the strong expression of the receptor in the developing hypothalamus (arrowhead) and rhombencephalon (asterisk). B) The sst2A
receptor immunoreactivity is intense at the outer border of the cerebellar neuroepithelium (asterisk) and the adjacent upper component of the
rhombic lip (rl). C) At E16, strong cellular sst2A receptor labeling is evident in the dorsal part of the cerebellum, where the progenitors of the external
granular layer (EGL) migrate. D,E) Pre-embedding immunogold immunohistochemistry of the sst2A receptor in the developing external germinal
layer at E16 illustrates that immunoparticles are predominantly localized at the internal surface of the plasma membrane (arrowheads). F,G) High
magnification confocal microscopic analysis of the developing EGL reveals redistribution of surface receptors to intracellular compartments upon
agonist stimulation. In control conditions, sst2A receptor immunoreactivity outlines the periphery of neurons (F). Forty minutes after agonist
administration, accumulation of immunoreactive puncta in the cytoplasm become evident (G). H) At P5, intense sst2A receptor immunofluorescence
is observed in the EGL. I–I0 represent magnification of boxed area in H. The sst2A receptor-immunoreactive neurons (red) are predominantly located
in the deep part of EGL (I). The Ki-67-immuonreactive proliferative neurons (green) are distributed predominantly in the superficial EGL (I9).
Accordingly only few sst2A receptor-immunoreactive neurons are Ki-67-positive (I0; arrowheads). J–J0) In the EGL, most sst2A receptor-
immunolabeled neurons (red in J, J0) are positive for the neuronal-specific nuclear protein NeuN (green in J9,J 0) (arrowheads) and demonstrate the
post-mitotic nature of sst2A-positive EGL neurons. K, K0) At P5, the large unipolar calretinin-immunoreactive brush cells (green in K9,K 0) are sst2A
receptor immunoreactive (red in K, K0). Note the colocalization of sst2A receptor and calretinin in a long brush cell process (arrowhead). cb, cerebellar
neuroepithelium; CB, cerebellum. Scale bars: A, 250 mm; B, H, K–K0,5 0mm; C, 20 mm, D, 200 nm; E, 400 nm. F, G, I–I0, J–J0,1 0mm.
doi:10.1371/journal.pone.0005509.g003
Sst2A and Brain Development
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5509Figure 4. Regional and cellular distribution of sst2A receptor immunoreactivity in the rat developing locus coeruleus. (A) At E18,
strong sst2A receptor immunoreactivity is found not only in the rhombic lip (rl) and external granular layer (EGL) but also in the rostro-ventral part of
the cerebellum between the cerebellar ventricular area (IV) and the ventral hindbrain (boxed area). B–B0) The large, elongated sst2A receptor-
immunoreactive cells (red in B, B0) lie parallel with the ventricular surface. These neurons also express tyrosine hydroxylase (TH; green in B9,B 0), a
marker of catecholaminergic neurons. C) At E21, intense sst2A receptor immunoreactivity (red in C, C0) is observed in the developing locus coeruleus
(LC) and overlap with TH immunolabeling (green in D9,D0). D represents high magnification of boxed area in C. Note that intense sst2A receptor
immunoreactivity (red) outlines the periphery of TH-positive (green) neurons (arrowheads). E) At P3, the locus coeruleus exhibits also strong sst2A
receptor immunoreactivity (red). The blue labeling represents DAPI staining. CB, cerebellum; IV, fourth ventricle. Scale bars: A, 200 mm; B–B0, C–C0,E ,
100 mm; D–D0,2 0mm.
doi:10.1371/journal.pone.0005509.g004
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absent in the ventricular zone. In the lateral cortical anlage, where
the first cortical plate neurons have migrated, the labeling was
mostly detected in the subventricular zone, at the limit with the
germinal zone. A lighter immunoreactive band was also observed
superficially in the marginal zone. Scattered immunoreactive cells
were evident in the subplate and cortical plate. From GW 12
onward, the cerebral wall is composed of the germinative zone
(divided into a ventricular and a subventricular zone), the
intermediate zone (future white matter), the subplate, the cortical
plate, and the superficial marginal zone (future layer I). At GW 12,
sst2A receptor immunoreactivity was observed in several layers in
the frontal lobe. In both medial and lateral cortices, a dense
immunoreactive band was observed in the subventricular zone.
Scattered, but strongly immunoreactive neurons, often displaying
a process perpendicularly oriented to the cortical surface, were
Figure 5. Regional and cellular distribution of sst2A receptor immunoreactivity on coronal sections of the prenatal human
cerebellum. A) At GW 19, intense receptor immunoreactivity (red in A, A0) is observed in the deep part of the external granular layer (EGL). Note the
large number of DAPI-positive cell nuclei (blue in A9,A 0) in the superficial EGL. B–B09 represent high magnification of boxed area in A. The sst2A
receptor immunoreactivity (red in B, B09) is mainly distributed in the deep part of the EGL whereas SRIF-immunoreactive cells (green in B9,B 09) are
mainly located in the deep part of the molecular layer (ML). C–C09) At GW 20, the high density sst2A receptor immunoreactivity (red in C, C09) in the
deep EGL is still present. In addition, intense receptor immunolabeling is detected in the internal granular layer (IGL; asterisk) and overlap with NeuN-
immunoreactive cells (green in C9–C09). D represents magnification of boxed area in C. The sst2A receptor is expressed in cells bodies located in the
deep part of the EGL. E–E09) In the IGL, the vast majority of NeuN- (green in E9,E 09) and DAPI- (blue in E0,E 09) positive cell nuclei are outlined by sst2A
receptor immunoreactivity (red in E, E09) (arrowheads), suggesting that the receptor is expressed by migrating granule cells. Scale bars: A–A0, C–C09,
100 mm; B–B09, D, E–E09,2 0mm.
doi:10.1371/journal.pone.0005509.g005
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5509Figure 6. Regional, cellular and subcellular localization of sst2A receptor immunoreactivity on sagittal (A–H) and coronal (I–K)
sections of the rat mesencephalon and diencephalon between E14 and E18. A) At E16, intense sst2A receptor immunoreactivity is observed
in the substantia nigra (SN; boxed area) and along the medial forebrain bundle (mfb; arrowhead). B–B0) At E16, the sst2A receptor (red in B, B0) and
tyrosine hydroxylase (TH) (green in B9,B 0) immunoreactivities extensively overlap both in the SN and in emerging processes of the mfb. C–C0) At E18,
sst2A receptor immunoreactivity is dramatically decreased in both the SN and the mfb. D–D0) High magnification microscopic images illustrate
numerous sst2A receptor-immunoreactive fibers (red in D,D9) in the mfb at E16. Some of them are TH-positive (green in D9,D0) (arrowheads). E–E0)
Some sst2A receptor-immunolabeled axons (red in E, E0) of the mfb express 5-HT (green in E9,E 0) (arrowheads). F,G) Pre-embedding immunogold
immunohistochemistry of the sst2A receptor in the mfb at E16 illustrates very high density of immunoparticles in axons (F) and growth cone-like
structures (G). Note that although the majority of immunoparticles are intracellular, some are found associated to the plasma membrane. H) At E14,
intense sst2A receptor immunolabeling is observed on sagittal sections in the developing hypothalamus (boxed area). I) Illustration of receptor
immunoreactivity on coronal section at the level of hypothalamic area at E16. Note the receptor immunoreactivity in the caudal ganglionic eminence
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cortical plate. This labeling was more intense in the lateral than in
the medial parts of the developing cortex. In the intermediate
zone, neuronal cells tangentially orientated to the cortical surface
displayed faint sst2A receptor labeling.
At GW 19 in parieto-temporal cortical areas, a slight receptor
labeling was still detected in the subventricular zone. More
conspicuous were the strongly immunoreactive cells and long
processes organized in clusters and chains within the middle part of
the cortical plate, and oriented perpendicularly to the cortical
surface (Fig. 11A–A0). Numerous processes extended to the
marginal zone. Double-labeling experiments clearly demonstrated
that thesecellsandprocesseswereincloseapposition with vimentin-
positive processes (Fig. 11B–B0), a marker of radial glia, suggesting
that these cells represent migrating clusters. At this developmental
stage, SRIF-immunoreactive fibers were found running along sst2A
receptor positive cell bodies and processes (Fig. 11C–C0).
From GW 21 to GW 23, the receptor labeling detected in the
subventricular zone at earlier stages could no longer be detected. A
denselabelingofradiallyorientedneuronswasvisualizedinthelayer
V. Their apical dendrites reached the layer I and were associated
with a diffuse immunolabeling there. In the upper subplate,
immunopositive neurons were numerous, whereas they were sparse
and dispersed in the inner subplate. The sst2A receptor immuno-
reactivity within the axonal component of the intermediate zone
almost disappeared. A similar distribution of receptor labeling was
detected in the visual cortical areas at the same developmental ages.
From GW 30 to birth in both fronto-parietal and occipital cortical
areas, the receptor labeling became weaker and more homoge-
neouslyand diffuselydistributed over the layers V–VI,a distribution
similar to that observed in the adult human brain [6,34].
In the rat hippocampal formation, the first immunoreactive cells
appeared at E16. They were round with short processes and
localized contiguous to the neuroepithelium in the intermediate
zone(Fig. 12A–A0). At all embryonic stages from E14 to birth, sst2A
receptor immunoreactivity was absent in proliferating precursor
cells located in the ammonic neuroepithelium, the primary dentate
neuroepitheliumor the secondary dentate matrix. BetweenE16and
E18, the labeling remained strong in the intermediate zone. In
addition, weak and diffuse sst2A receptor labeling was apparent in
the pyramidal cell layer and in the developing hilus of the dentate
gyrus. By E21, there was a substantial increase of immunoreactive
labeling in the pyramidal cell population as well as in the stratum
oriens and radiatum, while the intermediate zone still displayed the
highest amount of receptor immunoreactivity (Fig. 12B–B0, C–E).
At that fetal age, granule cells of the dentate gyrus began to express
the sst2A receptor. At P3, sst2A receptor labeling was widely
distributed in all strata and subfields of the Ammon’s horn and the
dentate gyrus, albeit more concentrated on the cell bodies and
proximal dendrites (Fig. 12F–H). Starting at P10, sst2A receptor
immunoreactivity was increasingly visible over more distal portions
of pyramidal and granular cell dendrites. By P21, sst2A receptor
immunoreactivity was essentially similar to that observed in
adulthood, i.e. diffusely distributed over the dendritic fields of
principal neurons.
A very dense but transient population of sst2A receptor-
immunoreactive cells was observed between P0 and P10 in the
anterior subventricular zone (SVZa) and the rostral migratory
stream (RMS) (Fig. 13). These cells were mainly localized at the
dorsal part of the SVZa/RMS and therefore represent a
subpopulation of this structure. They were positive for the
neuronal marker NeuN (Fig. 13D). Furthermore, following a
short pulse of BrdU (3 h), the BrdU-positive cells were found
negative for sst2A receptor immunoreactivity (Fig. 13E). These
results suggest that receptor expression is restricted to migrating
neuroblasts. Also, emanating from the border between the SVZa/
RMS and the frontal cortex, chains of neurons (from ,5t o,10
cells) were visualized entering the developing white matter towards
the deep layers of the cerebral cortex (Fig. 13A–A0 insets). Double-
labeling experiments with vimentin, a marker of radial glial cells,
clearly demonstrated that sst2A receptor-immunoreactive process-
es were found in close apposition to glial processes. Before
reaching the olfactory bulb, two streams of immunopositive cells
were visible in the ventral and dorsal parts of the RMS. However,
in the olfactory bulb proper, cells immunoreactive for the receptor
were not observed, suggesting that cells migrating radially lose
their receptor expression.
Functional approaches
Because the regional and cellular localization of the sst2A
receptor suggests a potential role on neuronal migration and
differentiation events, we next investigated the effects of receptor
activation in well characterized in vitro models. To assess the role of
the sst2A receptor on cell migration, EGL microexplant cultures
were treated with the sst2A receptor agonist octreotide (Fig. 14A).
In these cultures, granule cells migrate out without glial support
and follow the sequence of their in vivo differentiation pattern [35].
Migrating granule cells in EGL explants were sst2A receptor-
immunoreactive. The sst2A receptor was localized in cell bodies,
cellular processes and growth cones (Fig. 14B,C). In explants
treated with octreotide, the number of migrating granule cells and
the maximal migration distance from the explant increased
considerably when compared to control conditions (Fig. 14D,E).
Quantitative analysis indeed revealed a dose-dependent significant
increase of the migration rate of EGL neurons in octreotide-
treated explants as compared with controls (Fig. 14F). In contrast,
neurite outgrowth was similar in octreotide-treated and control
EGL microexplants (data not shown).
Next we analyzed the effect of sst2A receptor activation in the
regulation of axonal and dendritic patterning in low-density
primary hippocampal neuronal cultures. Young developing
neurons displayed intense sst2A receptor-immunoreactivity in cell
bodies, dendritic and axonal processes and growth cones
(Fig. 15A–A0). Agonist treatment at low concentration (10 nM)
did not modify neuronal morphology (Fig. 15B,C). By contrast,
quantitative analysis demonstrated a significant increase in the
length of axons in the 50 nM octreotide-treated group as
compared with controls (+9%; p,0.05) (Fig. 15D, E). The other
parameters studied (i.e. cell body surface, length of dendritic
processes, number and length of dendritic or axonal branches)
were not modified by octreotide treatment.
Discussion
This study provides the first systematic description of the
temporal and spatial expression pattern of a major SRIF receptor,
the sst2A subtype, in the pre- and postnatal rat brain and in the
developing human cerebral cortex and cerebellum. In addition, we
(CGE) (arrow). J,K) J represents magnification of boxed area in I. At high magnification, sst2A receptor immunoreactivity is found at the periphery of
numerous hypothalamic neurons. III, third ventricle; HA, hypothalamic area. Scale bars: A, 500 mm; B–B0, C–C0,5 0mm; D–D0, E–E0,J ,2 0mm; F, G, 1 mm;
H, 250 mm; I, 200 mm; K, 10 mm.
doi:10.1371/journal.pone.0005509.g006
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PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e5509Figure 7. Regional, cellular and subcellular distribution of sst2A receptor immunoreactivity on coronal sections of the rat
telencephalon at E16 and E18. A,B) Intense sst2A receptor immunoreactivity is detected at E16 in the post-mitotic areas of the lateral ganglionic
eminence (LGE) and the caudal ganglionic eminence (CGE) (B). Note the presence of sst2A receptor immunoreactivity in the cortex (cx) and
hippocampus (hi). C represents magnification of boxed area in B and illustrates that the sst2A receptor immunoreactivity is found in cell bodies and
short processes in the CGE. D,E) Pre-embedding immunogold immunohistochemistry of the sst2A receptor in the CGE illustrates that high density of
immunoparticles are localized intracellularly. However, sst2A receptor-immunoreactive particles are also found in association with the plasma
membrane (arrowheads in D). Note that in a neuronal process the majority of the immunoparticles are membrane-associated (arrowheads in E). F
represents magnification of the boxed area in A. Numerous cells are immunoreactive for sst2A in the LGE. G represents high magnification of the area
labeled with an arrow on A and illustrates that fibers are also sst2A receptor-immunolabeled. H,I) High magnification confocal microscopic analysisi n
the CGE demonstrates redistribution of receptors upon agonist stimulation. In control conditions, sst2A receptor immunoreactivity outlines the
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quences on developing neurons. Taken together, our results led to
six key findings. First, receptor expression in the rat brain is
detected early during ontogenesis (E12) and is restricted to post-
mitotic neuronal populations leaving the ventricular zone. Second,
the brain structures known to express the sst2A receptor at
adulthood also express this receptor during development. Only the
medial forebrain bundle, rostral migratory stream and cerebellum
expressed the receptor during development but not in adulthood.
Third, in contrast to the adult brain in which receptor localization
is mainly somatodendritic, some axons and growth cones were
found to strongly express the receptor during ontogenesis. Fourth,
the localization of receptor at the plasma membrane revealed by
electron microscopy and the change of its cellular distribution
following agonist challenge argue for functionality of the sst2A
receptor during neuronal development. Fifth, activation of sst2A
receptors indeed resulted in modification of neuronal migration
and neurite patterning in in vitro model systems. Sixth, the sst2A
receptor was detected both in rat and human developing neuronal
structures with remarkable similarities but also differences.
An intriguing feature of the ontogeny of sst2A receptor
expression in the brain is its preferential localization in neuronal
populations lying in the outer part of the germinal zone at
primitive developmental stages in rat and human brain tissues.
Double-labeling experiments confirmed that the vast majority of
these cells are not proliferative ones and represent young
neuroblasts en route to populate different regions of the developing
brain. The temporal coincidence of sst2 receptors and migrating
neurons suggest a role for this receptor during the neuronal
migration process. According to this hypothesis, we have
demonstrated that activation of the sst2A receptor in EGL
microexplants resulted in a dose-dependent increase of granule
cell migration. These results are in line with a previous in vitro
study [19] demonstrating that SRIF-28 increases the migration
rate of granule cells near their birthplace, but decreases it near
their final destination in the IGL. In both rats and humans, our
neuroanatomical data demonstrate the presence of the sst2A
receptor in the deep part of the EGL. Together, these studies
suggest that the sst2A receptor may be responsible for accelerating
the movement of granule cells in the early phase of migration. The
termination of migration in the IML could be regulated by
another somatostatin receptor in rat, possibly the sst1 receptor
[21]. In the developing human cerebellum, it remains to be
determined whether the sst2A receptor can assume both roles
since in addition to the EGL, it is also observed in the granule cells
of the IGL.
The persistent expression of the sst2A receptor in different brain
regions following the major migratory events suggests that it could
also have a role in neuronal differentiation. In line with this
hypothesis, sst2A receptor stimulation induced a moderate but
significant increase of the axonal length of hippocampal neurons in
culture. Such an effect was not found in EGL microexplants in
which sst2A receptor activation increased granule cell migration.
Thus depending on the regions and/or developmental time of
expression, the sst2A receptor is likely to assume different roles
during neuronal maturation.
In addition to the cerebellum, our morphological data suggest
involvement of sst2A receptor in neuronal migration in several
other brain areas. In the developing rat and human cerebral
cortex, the immunoreactive cells were found first in the preplate
and later in the deep intermediate/subventricular zone. These
particular regions contain the earliest-generated neurons of the
cortex that will migrate using the processes of radial glial cells to
reach their final position. In both rat and human cortex, sst2A
receptor-positive neurons were indeed found in close apposition
with vimentin-positive processes. Together, these results suggest
that the sst2A receptor could play a role in the early events of the
radial migration of cortical excitatory neurons.
In the developing forebrain, numerous sst2A receptor-positive
cells were visible in the LGE and CGE. These two areas
contribute to the development of numerous brain structures,
including the neocortex, striatum, thalamus, septum and olfactory
bulb for the former and nucleus accumbens, bed nucleus of the
stria terminalis, hippocampus, amygdala, striatum and globus
pallidus for the latter [36,37]. Interestingly, sst2A receptor-
expressing cells are indeed present during the course of maturation
in most of these brain regions, as illustrated in the striatum at E16,
in which strongly immunoreactive cells and processes are visible.
Neurons emanating from the LGE and the CGE usually use
nonradial migration to reach their final destination suggesting a
potential role of the sst2A receptor in the so-called tangential (or
neurophilic) neuronal migration [37]. By contrast, the absence of
sst2A receptor-expressing cells in the MGE (the major source of
cortical interneurons) together with the lack of a sst2A receptor-
positive cell stream between the developing subpallium and
cerebral cortex (an important pathway of migrating interneurons)
do not argue for a major role of this receptor in the migration of
GABAergic neocortical interneurons. In line with this observation,
using a gene expression microarray analysis on cortical interneu-
ron precursors, the sstr2 gene was found not to be enriched in this
population [38]. Of note, cortical interneurons, including the
somatostatinergic ones, do not express this receptor at adulthood
[39].
Between P0 and P10, a subpopulation of cells in the SVZ and
RMS were also sst2A receptor-positive. Cells born in the SVZ
migrate through chain migration along the RMS to the olfactory
bulb, where they differentiate into local interneurons [40]. Our
results clearly established that, like in other developing brain areas,
sst2A receptor-expressing cells were post-mitotic neuroblasts.
Additional investigations are required to determine whether the
sst2A receptor is a marker of a particular subpopulation of
migrating neuroblast and to analyze its potential motogenic role in
this cell population. It will be also of particular interest to
determine the nature and the final destination of sst2A receptor-
labeled neuroblasts that seem to detach from the dorsal part of the
SVZ and migrate to the white matter and/or the cerebral cortex.
Interestingly, transient expression of the sst2A receptor was
observed during the development of specific neuronal populations.
Thus, both 5-HT and TH expressing cells were strongly
immunopositive for the sst2A receptor between E15 and E17 in
the developing raphe nuclei and the VTA/SN, respectively. In
contrast, in adult rat brains, these regions were devoid of receptor
periphery of cells (H). Forty minutes after agonist administration, receptor immunoreactivity is confined to small puncta in the cytoplasm (I). J,K)A t
E18, intense sst2A receptor immunoreactivity is observed in the dorso-medial part of the caudate-putamen in rostral (J) and caudal (K) sections close
to the ventricular surface. Scattered sst2A receptor immunoreactivity is also evident in the medial part of the developing caudate-putamen (asterisk).
L represents magnification of boxed area on J. The sst2A receptor immunoreactivity is observed in large number of cells and their short processes in
the dorsal caudate-putamen. Note the lack of sst2A receptor immunoreactivity in the subventricular zone (SVZ). M,N are high magnifications from the
area labeled with asterisk on J. The sst2A receptor is expressed in neuronal perikarya and processes in the medial part of the caudate-putamen. Scale
bars: A, B, 200 mm; C, F, G, L, 20 mm; D, 500 nm; E, 250 nm; H, I, M, N, 10 mm; J, K, 500 mm.
doi:10.1371/journal.pone.0005509.g007
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observed at E16 in TH and 5-HT growing axons in the medial
forebrain bundle. The sst2A receptors are distributed on the entire
neuronal structure throughout soma-dendrites, axons and all the
way to the growth tip. Together these observations suggest that the
sst2A receptor may play a role, during a restricted time-window, in
the migration and normal positioning of TH and 5-HT neurons as
well as in axonal growth and guidance of these two cell
populations.
At the ultrastructural level, we found that a significant
proportion of sst2A receptors was associated with the plasma
membrane. Interestingly, the proportion of membrane-associated
receptors in the developing cortex was similar to that in the adult
cortex [39]. In our internalization assay experiments, sst2 receptor
Figure 8. Immunofluorescence of the sst2A receptor in coronal sections through the rat neocortical wall between E14 and P5. A–A09)
At E14, the sst2A receptor immunoreactivity is detected in the preplate (PP). Receptor immunoreactivity is observed in cell bodies and basal
processes perpendicular to the pial surface (A09). B–B09) At E16, intense receptor immunoreactivity is confined to neuronal cells located in the
subplate/intermediate zone (SP/IZ; defined by arrowheads). Immunolabeling is located in cell bodies and small processes of closely packed and
presumably migrating neurons (B09). C–C09) At E18, the sst2A receptor immunoreactivity is confined to cells in the intermediate zone but absent from
the adjacent subplate (defined by arrowheads). D–D09) At E21, sst2A receptor immunoreactivity is concentrated in the subventricular zone (SVZ) and
the adjacent deep part of IZ. Immunoreactivity is apparent in cell bodies and radially oriented processes (D, D09). E) At P5, the sst2A receptor
immunoreactivity is diffusely distributed over the neuropil. The labeling intensity decreases towards the deep layers. At high magnification, receptor
immunoreactivity appears diffusely distributed within the neuropil (E09). A09,B 09,C 09,D 09 and E09 represent magnifications of boxed areas on A0,B 0,C 0,
D0 and E0, respectively. CP/MZ, cortical plate/marginal zone; CP, cortical plate; MZ, marginal zone; VZ, ventricular zone; I–VI, cortical layers I to VI; WM,
white matter. Scale bars: A–A0, B–B0,5 0mm; C–C0, D–D0, E–E0, 100 mm; A09–E09,10 mm.
doi:10.1371/journal.pone.0005509.g008
Figure 9. Subcellular localization of sst2A receptor immunoreactivity in neocortical cells at E16. A–C) Pre-embedding immunogold
immunohistochemistry of the sst2A receptor in the developing cortex at E16 demonstrates localization of immunoparticles at the internal surface of
the plasma membrane (arrowheads). D,E) High magnification confocal microscopic analysis reveals agonist-induced redistribution of surface
receptors to intracellular compartments. In control conditions, sst2A receptor immunoreactivity outlines the periphery of cells (D). Forty minutes after
agonist administration, accumulation of immunoreactive puncta in the cytoplasm become evident (E). Scale bars, A, C, 500 nm; B, 1 mm; D, E, 10 mm.
doi:10.1371/journal.pone.0005509.g009
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PLoS ONE | www.plosone.org 14 May 2009 | Volume 4 | Issue 5 | e5509Figure 10. Regional and cellular distribution of sst2A receptor immunoreactivity in the human developing cortex. A,B) Embryonic
sagittal sections at GW 8 at the level of the medial cerebral cortex (A) reveals numerous receptor immunoreactive cell bodies (purple color) in the
preplate (PP) (inset box) and in the subventricular zone (SVZ). By contrast the ventricular zone (VZ) is devoid of receptor immunoreactivity. The red
color is due to the counterstaining of sections with neutral red. In the lateral part of the medial cerebral cortex (B), sst2A receptor immunoreactivity is
detected in the marginal zone (MZ), cortical plate (CP), subplate/intermediate zone (SP/IZ) and SVZ (inset box). C–E) At GW 12 in coronal sections,
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areas, indicating that receptors at plasma membrane can be
activated by agonists, as previously demonstrated in the adult rat
brain [30–32]. Taken together, these data clearly suggest that the
sst2A receptors are well poised to transduce the effects of
endogenous ligands early during embryonic life. The existence
albeit less intense, the pattern of receptor immunoreactivity is comparable to that observed at GW 8 with higher signals in the MZ (C,D) and SVZ (C,E).
D and E are magnifications of boxed areas in C at the level of the MZ and the SVZ, respectively. Note in D that some bipolar neurons expressing the
sst2A receptor are visible in the CP and in E that patches of labeling are observed in the SVZ contiguous to the VZ. F, G) In coronal sections at GW 23,
the labeling is present in neurons of CP (F) as well as in presumably post-mitotic migrating neurons in the IZ (G). H–J) In coronal sections at birth, the
labeling is diffusely distributed in layers II–III and V. In this latter layer some neurons positive for the sst2A receptor are also observed (I,J). Scale bars:
A, B, D, E, G, 25 mm; C, F, H, 100 mm; Inset in A,B and I,J, 10 mm.
doi:10.1371/journal.pone.0005509.g010
Figure 11. Regional and cellular distribution of the sst2A receptor immunofluorescence in the human cerebral cortex at GW 19. A–
A0) Intensely labeled sst2A receptor-immunoreactive neurons (red in A9–A0) form chain-like clusters in the middle part of the cortical plate (CP). Note
that long sst2A receptor-immunoreactive radial processes reach the pial surface (PS). B–B0) Receptor-immunolabeled cells and processes (red in B, B0)
are closely apposed by vimentin-positive processes (green in B9B0), suggesting migration of sst2A-labeled cells on radial glia. C–C0) Sst2A receptor-
immunoreactive processes (red in C, C0) are contacted by fibers that are immunoreactive for SRIF (green in D, D0) (arrowheads), the endogen ligand of
the receptor. Scale bars: 20 mm.
doi:10.1371/journal.pone.0005509.g011
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PLoS ONE | www.plosone.org 16 May 2009 | Volume 4 | Issue 5 | e5509Figure 12. Distribution of the sst2A receptor immunoreactivity in the rat hippocampus during pre- and postnatal development. A–
A0) At E16, sst2A receptor immunoreactivity (red in A, A0) is localized in the intermediate zone (IZ) of the hippocampus. Note the lack of
immunoreactivity in the ventricular zone (VZ). B–B0) At E21, the most intense immunolabeling is found in the intermediate zone of CA1. In addition,
less intense immunolabeling is apparent in the pyramidal cell layer as well as in the strata oriens and radiatum of CA1, in the CA3 and in the
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reported in the brain as early as E12 in rat [41–46]. In addition,
the mRNA encoding cortistatin has also been detected in the
developing brain [47]. Endogenous cortistatin may be an
additional physiological ligand of the sst2A receptor during brain
development. In the human brain, the present study demonstrates
the concomitant presence of the receptor and its ligand. SRIF
could also be transported from the maternal blood across the
placental barrier to the fetus, since somatostatin immunoreactivity
has been detected in human amniotic fluid [48].
The sst2A receptor distribution in rat and human developing
cortex and cerebellum exhibited similarities but also differences. In
this latter structure, the deep layer of EGL intensely expressed the
sst2A receptor in both species. In the IGL, however, migrating
granule cells in humans were receptor-immunopositive. By
contrast, in rats IGL, unipolar brush cells but not granule cells
expressed the receptor. Unipolar brush cells are a unique type of
glutamatergic interneurons that play an important role in
vestibulo-cerebellar circuitry [49]. They are produced in the
rhombic lip, a region with high density of sst2A receptor-positive
neuroblasts, and migrate to their final destination during late
embryonic and early postnatal development [50].
In the cerebral cortex, the sst2A receptor was located in the
preplate at early developmental stages in both rats and humans. As
soon as the cortical plate was formed, the sst2A labeling extended
to the entire intermediate zone/subplate in the rats whereas it was
enriched in the outer part of the germinal zone in humans. The
latter location in humans emphasizes the possible role of sst2A
developing dentate gyrus (DG). C) In the hilus of the DG, sst2A receptor immunoreactivity appears diffusely distributed. D represents magnificationo f
the area labeled with asterisk in B and illustrates the diffuse sst2A receptor immunolabeling observed in the CA1 pyramidal cell layer. E represents
magnification of boxed area in B. The sst2A receptor immunolabeling is intense in cells of the IZ whereas the subventricular zone (SVZ) is devoid of
labeling. F) At P3, intense immunofluorescence is detected in the pyramidal layer, strata oriens and radiatum of CA1-3, as well as in the hilus of DG.
The molecular layer of dentate gyrus is weakly immunoreactive. G represents magnification of boxed area in F and illustrates the intense sst2A
receptor immunolabeling localized in CA1 pyramidal cell bodies and proximal dendrites. H represents magnification of area labeled with asterisk in F
and illustrates the diffuse sst2A receptor immunolabeling observed in the hilus of the DG. Scale bars: A–A0, B–B0, F, 100 mm; C, D, E, G, H, 20 mm.
doi:10.1371/journal.pone.0005509.g012
Figure 13. Immunofluorescence of sst2A receptor in the rat perinatal rostral migratory stream. A–A0) In sagittal sections at P0, an
intense band of sst2A receptor immunoreactivity is observed from the anterior subventricular zone (SVZa), through the rostral migratory stream
(RMS) and ending in the olfactory bulb (OB). From the SVZa, shown in detail in the high magnification insets, chains of immunoreactive neurons
perpendicular to the SVZa long axis extend into the white matter of the overlying cerebral cortex. B–B0 represents high magnification of the area
labeled with asterisk in A. The sst2A receptor immunoreactive cells are principally localized along the ventral and dorsal surface of RMS. C) High
magnification of sst2A receptor immunoreactivity at the entrance of RMS into the olfactory bulb at P5 illustrates immunoreactive cells at the surface
of the stream as well as embedded in central position. D) In the dorsal part of the RMS, sst2A receptor-immunoreactive cells (red) contain NeuN
labeling in their nuclei (green; arrowhead). E) Sst2A receptor- (red) and NeuN- (blue) double-labeled cells (arrowhead) of the RMS do not contain BrdU
immunoreactivity (green), demonstrating that receptor expression is restricted to post-mitotic neurons. Scale bars: A–A0, 500 mm; B–B0, C, 100 mm; D,
20 mm; E, 10 mm.
doi:10.1371/journal.pone.0005509.g013
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neuronal proliferation period which last about 3 months. Later in
development the sst2A cortical labeling evolved towards the deep
layers as detected in the adult in both species.
In conclusion, our observations strongly suggest that in addition
to its neuromodulatory role in the adult brain, the sst2A receptor
participates in the development and maturation of specific neuronal
populations during brain ontogenesis in both rats and humans.
Materials and Methods
Animals
Pregnant Sprague Dawley rats were purchased from Janvier
Laboratories (Le Genest St Isle, France). The breeding was made
during the night and the day after insemination was considered as
embryonic day 0.5. The day of birth was designated as P0. Three
to four male and female per stage were studied at the following
ages: E10, E12, E13, E14, E16, E18, E21, P0, P3, P5, P7, P10 and
P21. All experiments were carried out in accordance to the ethical
principles of the Institut National de la Sante ´ et de la Recherche
Me ´dicale (INSERM).
Human samples
Brain tissues of human embryos and fetuses of 8,9,12,19,21, 23,
30, 35 and 38 gestational weeks (GW) were used in this study
[51,52]. Written consent was routinely obtained from parents, and
approval for the study were given by the French National Ethics
Committee (CCNESVS,approval number90 294) inaccordanceto
Figure 14. Effect of sst2A receptor activation on in vitro granule cell migration. A) Representative image of an external granular layer (EGL)
microexplant after 3 days in vitro in culture. The core of the explant and surrounding scattered migrating granules cells are labeled with DAPI (blue).
Neuronal processes are labeled by neuronal class III b-tubulin immunoreactivity (green). B) In individual granule cells, sst2A receptor
immunoreactivity is visible in both neuronal perikarya and processes (red). C) Illustration of sst2A receptor immunolabeling (red) in a b-tubulin-
immunoreactive (green) axon. Note the sst2A-immunoreactive puncta in a growth cone structure (arrow). D, E) In comparison to control (D) the
number of migrating granule cells is significantly increased in 100 nm octreotide-treated EGL (E) microexplants. The octreotide-induced granule cell
migration increase is dose-dependent as revealed by quantitative analysis (F). *p,0.05; **p,0.01; ***p,0.001. Values represent mean6SEM. Scale
bars: A, D, E, 500 mm; B, C, 10 mm.
doi:10.1371/journal.pone.0005509.g014
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2000). Cerebral tissues were fixed in 4% paraformaldehyde in
phosphate buffer (pH 7.4, 0.12 M) for 8 h, rinsed and cryopro-
tected in phosphate buffer supplemented with 20% sucrose. Serial
sagittal or coronal 12 mm-thick cryostat sections were obtained and
processed for immunocytochemistry as mentioned below.
Figure 15. Effect of sst2A receptor agonist on axonal and dendritic patterning. A–A0) Representative image of sst2A receptor localization in
a primary hippocampal cell after 24 h in vitro in culture. Receptor immunoreactivity (green in A, A0) is present in the cell body and processes. Cell
morphology is revealed by actin-binding protein phalloidin (red in A9,A 0). Note that sst2A receptor immunoreactivity is also present in growth cones
(insets in A–A0). B–D) Representative images of neurons from control (ctrl; B), 10 nM octreotide-treated (10 nM oct.; C) and 50 nM octreotide-treated
(50 nM oct.; D) cultures. Arrows depict the axonal process which appears longer when cells are treated with 50 nM octreotide. E) Quantitative analysis
reveals that the axon length (right panel) is significantly increased in the 50 nM oct. group when compared to the control group. The mean cell body
surface (left panel) and the mean dendritic length (middle panel) are not modified by sst2A receptor agonist treatments. Values (mean6SEM) are
expressed in relation to an arbitrary unit (100%) of the control values. *p,0.05; ns, not significant. Scale bars: A–A0, B–D, 20 mm.
doi:10.1371/journal.pone.0005509.g015
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Primary antibodies. The sst2A receptor was
immunolocalized by using an antiserum raised in rabbit
against the C-terminal segment 330–369 of the human protein
(1/5000) that specifically recognized sst2A antigens in rat and
human brain sections by immunohistochemistry as previously
demonstrated [6,53–55]. Immunocytochemical controls for sst2A
receptor labeling consisted of adsorption of the antibody with
50 mg/mL of sst2A receptor-GST fusion proteins overnight at
4uC, and incubation with the preimmune in place of the
immune serum.
Several antibodies were used in double-labeling experiments to
characterize cells and processes expressing the sst2A receptor. For
a comprehensive list of the antibodies and their characteristics, see
Table 1. Controls for double-labeling staining included omission of
the primary antibodies to test for nonspecific binding of the
secondary antibodies and incubation with one primary but both
secondary antibodies to demonstrate the absence of cross-labeling.
Tissue preparation. Pregnant females were sacrificed by
cervical dislocation and the abdominal cavity was opened to
remove embryos. The brains of embryos were quickly dissected
and fixed in 4% paraformaldehyde (PFA) in 0.12 M phosphate
buffer, pH 7.4 (PB) overnight at 4uC. Pups were anesthetized with
isofluorane and intracardially perfused for 5 min with 4% PFA in
PB. Brains were immediately removed and postfixed in the same
fixative overnight at 4uC. All specimens were then cryoprotected
for 2 days in a 10% sucrose solution in PB at 4uC. Brains were
immerged in a solution of 7.5% gelatin, 10% sucrose in PB for 1 h
at 37uC. They were after embedded in a block of the same solution
for 1 h at 4uC. Brains were frozen in liquid isopentane at 270uC
and stored at 280uC until sectioning. Parasagittal or coronal
sections (10 mm of thickness) were cut on a cryostat and collected
on Superfrost plus slides (Microm Microtech, Francheville,
France).
Immunoperoxidase procedure. Cryostat sections were air-
dried and underwent 10-minute rinses in 0.1 M phosphate buffer
saline, pH 7.4 (PBS). They were then washed twice 10 min in
0.2% gelatin/0.25% Triton X-100 in PBS. Primary and secondary
antibodies were incubated in 0.25% Triton X-100 with 10% goat
normal serum in PBS to block the nonspecific binding sites and aid
permeabilization. Primary sst2A antibody (1:5000) was incubated
overnight at 4uC. After rinsing in PBS, the rabbit anti-sst2A
antiserum was detected using a 90 min incubation in a
biotinylated goat anti-rabbit IgG (1:200, Sigma-Aldrich, St.
Louis, MO) solution followed by a 90 min incubation in an
avidin-biotin-peroxidase complex reagent (1:400, Amersham
Pharmacia Biotech, Buckinghamshire, UK) at room
temperature. Peroxidase enzyme activity was revealed using 3,
39- diaminobenzidine tetrahydrochloride (DAB; 0.01%) in 0.05 M
Tris buffer saline, pH 7.6, in the presence of 0.002% H2O2 and
0.6% nickel ammonium sulfate. Finally, the sections were rinsed in
distilled water and dehydrated through graded ethanols, treated
with xylene and coverslipped with Permount (Fisher Scientific,
Pittsburgh, PA) for light microscopic examination.
Double labeling immunofluorescence procedure.
Mixtures of primary antibodies were incubated overnight at 4uC
in a 10% donkey normal serum/0.2% gelatin/0.25% Triton X-
100 in PBS solution. The following day, sections were rinsed three
times in 0.2% gelatin/0.25% Triton X-100 in PBS, followed by a
90 min incubation in a mixture of appropriate secondary
antibodies. Secondary antibodies used were cyanine 3 (Cy3)-
conjugated donkey anti-rabbit (1:300, Jackson ImmunoResearch,
West Grove, PA), Alexa Fluor 488 (A488)-conjugated donkey anti-
mouse, A488-conjugated donkey anti-goat and A488-conjugated
donkey anti-rat (1:200, Invitrogen, Carlsbad, CA). They were
incubated in 10% donkey normal serum/0.2% gelatin/0.25%
Triton X-100 in PBS. After three further rinses in PBS, sections
were stained for few seconds with DAPI (1:1000), rinsed in PBS
Table 1. List of Primary Antibodies.
Name Immunogen Source
Catalog
Number Host and type
Clone/
Code Dilution
Species
reactivity Ref.
Calretinin human recombinant
calretinin
Swant, Bellinzona,
Switzerland
goat polyclonal CG1 1:1000 human, rat [62]
GAD67 recombinant GAD67 Chemicon, Temecula, CA MAB5406 purified mouse
monoclonal IgG2a
1G10.2 1:1000 human, rat [63,64]
GFAP purified GFAP from pig
spinal cord
Sigma-Aldrich, St. Louis,
MO
G6171 purified mouse
monoclonal
G-A-5 1:1000 human, rat [65,66]
Ki-67 recombinant human
Ki-67 peptide
BD Biosciences
Pharmingen, San Diego, CA
556003 purified mouse
monoclonal IgG1k
B56 1:200 human, rat [67,68]
NeuN purified cell nuclei from
mouse brain
Chemicon MAB377 purified mouse
monoclonal IgG1
A60 1:1000 human, rat [69]
Neuronal Class III
b-Tubulin
rat brain microtubules Covance, Berkeley, CA MMS-435P purified mouse
monoclonal IgG2a
TUJ1 1:1000 human, rat [70,71]
Serotonin serotonin conjugated to
BSA
Chemicon MAB352 rat monoclonal YC5/45 1:500 human, rat [72]
Somatostatin human SRIF C-terminus Santa Cruz Biotechnology,
Santa Cruz, CA
sc-7819 purified goat polyclonal
IgG
D-20 1:500 human, rat [6,55]
Somatostatin 2A
receptor
recombinant human
sst2A receptor
Lone Helboe rabbit polyclonal 1:5000 human, rat [6,39]
TH TH purified from
PC12 cells
Chemicon MAB318 ascites mouse
monoclonal IgG1k
LNC1 1:1000 human, rat [73,74]
Vimentin purified vimentin from
pig eye lens
Santa Cruz Biotechnology sc-6260 mouse monoclonal IgG1 V9 1:400 human, rat [75,76]
doi:10.1371/journal.pone.0005509.t001
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Birmingham, AL) for fluorescence microscopic examination.
Sst2A receptor internalization essay
The brains of three E16 embryos were quickly dissected and
immediately immersed for 40 minutes at 37uC, 5% CO2 in a
solution of artificial cerebrospinal fluid (25 mM KCl, 2 mM
KH2PO4, 25 mM Hepes, 37 mM D-glucose, 10 mM MgSO4 and
175 mM sucrose) containing 100 mM sst2A receptor agonist
octreotide (SMS 201–995) or PBS (control). After 40 minutes,
brains were fixed in 4% PFA in PB overnight at 4uC and processed
for sst2A receptor immunofluorescence staining as describe above.
Brain sections were analyzed using a Zeiss Axio Observer inverted
microscope equipped with a LSM 5 Exciter confocal scanning
system (Carl Zeiss, Jena, Germany).
BrdU incorporation assay
Three P5 rat pups were injected intraperitoneally with a
solution of 5-bromo-29-deoxyuridine (BrdU, Sigma; 50 mg/kg
body weight) 3 h prior to perfusion with 4% paraformaldehyde.
After fixation, brains were processed for immunohistochemistry as
described above. Cryostat sections were air dried, denatured
30 min in 2 N HCl in PBS, and rinsed three times in PBS. BrdU
incorporation was visualized by immunofluorescence using a rat
anti-BrdU monoclonal antibody (1:200, Abcam, Cambridge, UK)
and an A488-conjugated donkey anti-rat antibody (1:200,
Invitrogen).
Electron microscopy
Immunocytochemical procedures for the detection of the sst2A
receptor at the ultrastructural level were performed as previously
described [30,39]. Briefly, the brains of embryos were quickly
dissected and fixed in 4% PFA with 0.05% glutaraldehyde in PB
for 2 h at 4uC. Brains were post-fixed overnight in 4% PFA in PB
at 4uC, washed in 0.01 M phosphate-buffered saline, pH 7.4 (PBS)
and embedded in 4% Agarose type LM SIEVE (Euromedex,
Souffelweyersheim, France). Sagittal sections were cut on a
vibratome at 50 mm and collected in PBS. Sections were
equilibrated in 25% sucrose and 10% glycerol in 0.05 M PB,
frozen rapidly in isopentane, cooled in liquid nitrogen and thawed
in PBS at room temperature. Sections were then incubated in 5%
normal goat serum (NGS) in PBS for 30 min and incubated for
16 h at room temperature in anti-sst2 receptor antibody diluted
1:800 in PBS containing 1% NGS. After washing in PBS, they
were incubated for 2 h in a 1:100 dilution of NANOGOLD- goat
anti-rabbit IgG (1.4 nm in diameter; Nanoprobes, Stony Brook,
NY) in PBS containing 2% of bovine serum albumin-c and 0.2%
of cold water fish gelatin. Sections were then washed in PBS and
post-fixed in 1% glutaraldehyde in PBS for 10 min. After repeated
washing in PBS and 0.1 M sodium acetate buffer, pH 7.0, gold
labeling was intensified using a silver enhancement kit (HQ Silver;
Nanoprobes) for 5 min in the dark at room temperature. Sections
were finally washed in acetate buffer and then in PB.
Immunogold-treated sections were post-fixed in 1% osmium
tetroxide in PB 0.1 M for 10 min at room temperature. After
washing three times in PB, they were dehydrated in an ascending
series of ethanol, which included 1% uranyl acetate in 70%
ethanol. They were then treated with propylene oxide twice for
10 min, equilibrated overnight in Durcupan ACM (Fluka, Buchs,
Switzerland), mounted on glass slides and cured at 60uC for 48 h.
Areas of interest were cut out from the slide and glued to blank
cylinders of resin. Immunoreactive samples identified on thick
sections were cut in semithin sections (1 mm) and then in ultrathin
sections on a Reichert Ultracut S microtome. Ultrathin sections
were collected on pioloform-coated single-slot grids. Sections were
stained with lead citrate and examined with a Philips CM120
electron microscope. The subcellular distribution of sst2 receptor
in the developing cortex, cerebellum and ganglionic eminence was
analyzed as previously described [30,39]. Plasma membrane-
associated and intracellular immunoparticles were counted. The
relative distribution of the membrane-associated and intracellular
receptors was calculated in relation to the total number of
receptors per cells and expressed in percentage.
In vitro experiments
Microexplants culture. External granular layer
microexplants cultures of P3 rats were prepared as described
previously [35,56]. To test the effect of sst2A receptor activation
on granule cell migration, octreotide (0, 20, 100 nM) was added to
the culture medium once per day on day in vitro (DIV) 1–3.
Explants were fixed on DIV 3 with 4% PFA and 4% sucrose in
PB. For permeabilization and blocking of unspecific binding of
antibodies, the explants were pre-incubated with 10% normal
donkey serum and 0.2% gelatin in PBS for 30 min. Cultures were
then incubated in rabbit sst2A receptor (1:5000) and mouse
neuronal class III b-tubulin (1:500, Covance, Berkeley, CA)
primary antibodies overnight at room temperature, then in Cy3-
conjugated donkey anti-rabbit (1:300, Jackson ImmunoResearch)
and A488-conjugated donkey anti-mouse (1:200, Invitrogen)
secondary antibodies in 1% NDS/0.2% gelatin/0.1% saponin in
PBS for 90 min. Explants were stained for few seconds with DAPI
(1:1000), rinsed in PBS and coverslipped with Fluoromount-G
(SouthernBiotech) for fluorescence microscopic examination.
Migration analysis was performed using the MetaMorph
software (Molecular Devices, Downingtown, PA) as described
previously [56,57]. Twenty three control, twenty-four 20 nM
octreotide-treated and nineteen 100 nM octreotide-treated ex-
plants were analyzed. To measure migration rates, concentric
areas at increasing distances from the explant border were
delimited. The number of DAPI-labeled pixels within each area
was counted and then expressed as a percentage of the total
number of pixels. To evaluate the overall rate of neuronal
migration, the total number of DAPI-labeled pixels surrounding
the explants was counted. Neuritic length was estimated by laying
out a circle containing approximately 90% of the ß-III-tubulin
positive neurites. Values from control and octreotide-treated
explants were analyzed by Kruskal-Wallis nonparametric test
followed by Dunn’s multiple comparison test using GraphPad
Prism version 4.03 (GraphPad Software, San Diego, CA). The
value of p,0.05 was considered as statistically significant.
Low density cultures of primary hippocampal
neurons. Primary hippocampal neuron culture was prepared
as described previously [58–60]. Two hours after plating,
octreotide (0, 10 or 50 nM) was added to the neurons in Petri
dishes and incubated for 24 h in the presence of feeder glia.
Neurons were fixed with 4% PFA and 4% sucrose in PB for
20 minutes before permeabilization and blocking with 0.066%
saponin, 0.22% gelatin in PB. Cells were incubated for 1 h in
rabbit sst2A receptor (1:5000) and mouse neuronal class III b-
tubulin (1:500, Covance) primary antibodies in 1% NDS/0.2%
gelatin/0.1% saponin in PBS, followed by 45 min incubation in
A488-conjugated donkey anti-rabbit (1:200, Invitrogen) and Cy5-
conjugated donkey anti-mouse (1:500, Jackson ImmunoResearch)
secondary antibodies together with phalloidin-A546 (1:250,
Invitrogen). Coverslips were mounted using Fluoromount-G
(SouthernBiotech) containing Hoechst 33342 (10 mg/mL, Sigma).
Morphological analysis was performed as described previously
[61]. Images of phalloidin-A546-labeled neurons were acquired
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and seventy nine control neurons, 276 10 nM octreotide-treated
and 231 50 nM octreotide-treated neurons were analyzed.
Number and length of processes, including axonal and dendritic
branches, as well as areas of cell bodies were measured using
Image J (National Institutes of Health, Bethesda, MD). Among the
primary processes, the axon was defined as the longest process,
whereas the other processes were classified as dendrites. Values
from control and octreotide-treated explants were analyzed by
Kruskal-Wallis nonparametric test followed by Dunn’s multiple
comparison test using GraphPad Prism version 4.03. The value of
p,0.05 was considered as statistically significant.
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